Point72 (DIFC)’s Xeris Biopharma Holdings XERS Stock Holding History

Point72 (DIFC)’s Portfolio XERS Stock Details XERS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-1,627	Closed	-$7.6K	–	1948
2025 Q2	$7.6K	Buy	+1,627	New	+$7.46K	﹤0.01%	1344

Other funds holding XERS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return

Point72 (DIFC)'s XERS Position: Q3 2025 in Review

Point72 (DIFC) sold out of Xeris Biopharma Holdings (XERS) in Q3 2025, closing a stake of 1,627 shares — an estimated $7.6K sold.

Point72 (DIFC) first reported a position in XERS in Q2 2025 and held it in 1 quarter. The position peaked at $7.6K in Q2 2025. 230 funds tracked by Wall St. Rank hold XERS as of Q3 2025.

Point72 (DIFC) reported no remaining Xeris Biopharma Holdings position as of Q3 2025 after selling out during the quarter.
Point72 (DIFC) sold 1,627 Xeris Biopharma Holdings shares in Q3 2025, an estimated $7.6K.
Point72 (DIFC) first reported a position in Xeris Biopharma Holdings in Q2 2025 and held it in 1 quarter.
Point72 (DIFC)'s Xeris Biopharma Holdings position peaked at $7.6K in Q2 2025.
230 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q3 2025.

Based on Point72 (DIFC)'s 13F filing for Q3 2025, filed 14 Nov 2025.